Drugs / Vofatamab
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02925533 | Dec 2016 → Jun 2017 | urinary bladder cancer | Mark Pomerantz, MD | Terminated | No outcome recorded |
| Phase 1 | NCT01363024 | Aug 2011 → Mar 2013 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01122875 | Nov 2010 → May 2012 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05363605 | Apr 2022 → Sep 2023 | breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +4 | Fusion Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03123055 | Apr 2017 → Dec 2019 | urinary bladder disorder, urothelial carcinoma | Rainier Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02401542 | Jun 2015 → Nov 2019 | urinary bladder disorder, urothelial carcinoma | Rainier Therapeutics | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vofatamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05363605 ↗ |
| Known as | Anti-FGR3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297848 ↗ |
| Known as | B-701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03123055 ↗ |
| Known as | MFGR-1877A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297848 ↗ |
| Known as | MFGR1877S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01122875 ↗ |
| Known as | RG-7444 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297848 ↗ |
| Action | Inhibit | “Novel FGFR3 Inhibitor (B-701)” NCT03123055 ↗ |
| Modality | Monoclonal antibody | “Vofatamab is a novel monoclonal antibody specific for fibroblast growth factor receptor 3 (FGFR3)” NCT02401542 ↗ |
| Route | Intravenous | “Intravenous repeating dose” NCT01122875 ↗ |
| Target | FGFR3 | “specific for fibroblast growth factor receptor 3 (FGFR3)” NCT02401542 ↗ |